<DOC>
	<DOCNO>NCT00116402</DOCNO>
	<brief_summary>The purpose study evaluate blood airway subject mild moderate COPD undergo standard treatment .</brief_summary>
	<brief_title>A Pilot Study Mechanism Synergism Between FP Salmeterol Preventing COPD Exacerbations</brief_title>
	<detailed_description>Our objective examine mechanism additive/synergistic property b2-adrenoceptor stimulation corticosteroid receptor activation : - Preventing neutrophil adhesion specific endothelial ligand , e.g . ICAM-1 - Undergoing activation consequence adhesion . We hypothesize combination therapy salmeterol + fluticasone ( FP ) : - Augment inhibition adhesion neutrophil obtain peripheral blood study subject vitro , block gIV-PLA2 translocation nuclear membrane eosinophil ; - Augment inhibition transendothelial migration neutrophil airways subject chronic obstructive pulmonary disease ; - Augment number concentration pro-inflammatory product bronchoalveolar lavage fluid ; - Decrease number neutrophils bronchial tissue endobronchial biopsy treat patient .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<criteria>Males female &gt; 50 year age Physiologic evidence COPD define per ATS guideline : cigarette smoke history &gt; 20 pack year , FEV1/FVC &lt; 70 % Patients must postbronchodilator FEV1 &gt; 50 % predict value enrollment Patient must O2 saturation measure pulse oximetry &gt; 90 % RA Must able participate study , willing give inform consent , comply study restriction Women childbearing potential defined female less 5 year post menopausal unless hysterectomy bilateral oophorectomy Observation solitary nodule lung require medical intervention Patients maintenance therapy oral steroid Patients giant bullous disease Significant medical condition , opinion investigator , interfere patient 's ability perform study test Presence coagulopathy define platelet count &lt; 100,000/mm3 , PT PTT &gt; 1.2 x upper limit normal Concurrent enrollment participation clinical trial within past 30 day Primary diagnosis asthma History alpha 1 antitrypsin deficiency Any clinically significant active pulmonary disease could contribute dyspnea Current systemic inhale steroid theophylline</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>COPD</keyword>
	<keyword>Chronic Obstructive</keyword>
	<keyword>Pulmonary Disease</keyword>
	<keyword>Inhaled Corticosteroids</keyword>
	<keyword>Airway Inflammation</keyword>
	<keyword>Bronchoscopy</keyword>
</DOC>